/PRNewswire/ Significant breakthroughs in the rapid and cost-effective analysis of the human genome have brought clarity to the path of discovering the.
Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF) Short Interest Down 19.4% in November kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Santhera Pharmaceuticals Holding AG announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer . Both will join the.
Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commissi
Santhera Pharmaceuticals Holding AG: Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.